

Message

From: Matt Hancock [matt.hancock@digital.dhsc.gov.uk]
Sent: 30/06/2020 12:31:59 PM
To: Lord Bethell [LordBethell@dhsc.gov.uk]
Subject: Fwd: Anitgen Testing Problems/Solutions
Attachments: Att 1f- Covid-19 testing - learning from Ebola.pdf; Untitled attachment 00008.htm; FW: Data from LSG in relation to inactivating materials and alternatives to VTM; Untitled attachment 00014.htm; Att 1a- Jenny Murray email.docx; Untitled attachment 00017.htm; Att 1e -PHE 2020602_EvidenceReport_SWT012e 1.0.pdf; Untitled attachment 00020.htm; Att 1d- PHE 2020517_EvidenceReport_CI_SWTC008c_v1.0.pdf; Untitled attachment 00023.htm; Att 1c - PHE 20200428_EvidenceReport_SWTC007_v1.0.pdf; Untitled attachment 00026.htm; Att 2 - Points from large dsitributor.docx; Untitled attachment 00029.htm

Importance: High

I think this is a very interesting critique from someone who turned his business to testing when the crisis broke. He's a very impressive guy and quite a good analysis. Thoughts?

M

Begin forwarded message:

From: Alexander Bourne <info@hinpack.com>
Subject: Anitgen Testing Problems/Solutions
Date: 30 June 2020 at 11:56:26 BST
To: "matt.hancock@digital.dhsc.gov.uk" <matt.hancock@digital.dhsc.gov.uk>

Dear Matt,

Thank you for your time on Saturday. I think it is important to clarify that it is the belief of all I have encountered that the policy on testing overall has been very good and achieved great things in a short period of time. The overall feeling is that now the panic is over, we should be able to get into a rhythm that allows for consistent production/processing and redundancy to allow for surge manufacturing and testing in the event of outbreak or the need for larger scale surveillance. I have summarised all of the points that I have picked up from interviewing the following people over the last few days. Their correspondence and supporting documents are attached for reference. Most didn't want to give names but I have described their positions.

Jenny Murray, Life Sciences Group – manufacturers of viral transport media, inactivating transport media and funded by Innovate UK to research non-guanidine based inactivating transport media.
Alex Bourne, Hinpack Limited- manufacturer of specimen collection tubes in strategic partnership with VWR/Avantor.

A former Vice President of a major Pharmaceutical company seconded to the DHSC, since moved on.
Senior Manager at Deloitte embedded in the Lighthouse network.

A Professor of Medicine involved with the DHSC in several capacities.

A process manager to the lighthouse laboratory in Cambridge.

A lighthouse laboratory manager/administrator.

A total of 8 lighthouse laboratory operators/technicians or logistical staff.

NB: This only concerns antigen testing.

Summary of Points